Trial reportJournal of the American Heart Association2025
Latent Cytomegalovirus Infection Is Associated With Impaired Left Ventricular Function After ST-Segment-Elevation Myocardial Infarction.
Trial report in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cytomegalovirus Latency Fuels Inflammation Following Myocardial Infarction.Circulation research · 2026Article
- T Cell Receptor Repertoires Across the Continuum of Vascular, Myocardial, and Age-Related Diseases.Immunological reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman cytomegalovirus is a herpes virus that affects most individuals globally and may increase the risk of cardiovascular disease. Whether cytomegalovirus influences outcomes after ST-segment-elevation myocardial infarction (STEMI) is unknown. Our objective was to investigate the association between latent cytomegalovirus infection and outcomes after STEMI.
methodsThis study includes 354 patients with STEMI who were recruited to T-TIME (A Trial of Low-Dose Adjunctive Alteplase During Primary PCI) and had blood samples cryopreserved. Participants underwent immediate percutaneous coronary intervention, serial cardiovascular magnetic resonance imaging at 2 to 7 days and 3 months post-STEMI, and assessment of health-related quality of life with the EuroQol 5-Dimension visual analog scale. Cytomegalovirus Ig (immunoglobulin) G titer was measured in cryopreserved baseline samples from each patient. Results were adjusted for age and other possible confounders.
resultsOne hundred seventy-five patients (49.4%) were cytomegalovirus IgG titer-negative, 89 (25.1%) were low-positive, and 90 (25.4%) were high-positive. Patients who were cytomegalovirus-positive were older (62.5 versus 58.7 years of age) and more likely to be non-White (6.7% versus 2.3%). Myocardial reperfusion, measured by ST-segment resolution, was less successful in patients who were cytomegalovirus-positive (38.7% resolution versus 48.4%; adjusted
conclusionsPatients who are cytomegalovirus-positive with STEMI have impaired reperfusion, reduced left ventricular function, and less improvement in health-related quality of life over 3 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.